Distinguished in Mycobacterium Avium Complex Infections

Takashi Ogura

Yokohama, JP 
Distinguished in Mycobacterium Avium Complex Infections
Yokohama, JP 
OverviewLocationsClinical Research

Overview

Takashi Ogura practices in Yokohama, Japan. Mr. Ogura is rated as a Distinguished expert by MediFind in the treatment of Mycobacterium Avium Complex Infections. His top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Endoscopy, and Lung Transplant.

His clinical research consists of co-authoring 436 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Mycobacterium Avium Complex Infections.

Gender
Male

Locations

Yokohama, 2360051, Japan
Other Locations
Kashiwa, Japan
Kanagawa, Japan
St Marianna University School of Medicine
Kawasaki, Japan
Osaka, Japan
Kanazawa, 2360051, Japan
Ako, 6781297, Japan
Japan
Kanazawacho, 2360051, Japan
Tamagawa, Japan
Kamigori, 6781297, Japan
Tsukuba, 3058571, Japan
Chiba, Japan
Hamamatsu, Japan
Saitama, Japan
Sayo, 6795148, Japan
Nagoya, 4668555, Japan
Hachioji, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Japanese Idiopathic Interstitial Pneumonias Registry
Japanese Idiopathic Interstitial Pneumonias Registry
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
View 2 Less Clinical Trials

436 Total Publications

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
Journal: ESMO open
Published: July 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ogura's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 64 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile